These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32437559)

  • 1. Clogging up the pipeline: factor VIII aggregates.
    Sabatino DE
    Blood; 2020 May; 135(21):1825-1827. PubMed ID: 32437559
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of desmopressin on plasma factor VIII and von Willebrand factor concentrations in Greyhounds.
    Sato I; Parry BW
    Aust Vet J; 1998 Dec; 76(12):809-12. PubMed ID: 9972432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
    Rivard GE; Aledort L;
    Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the management of von Willebrand disease.
    Federici AB
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
    Goudemand J
    Haemophilia; 2007 Dec; 13 Suppl 5():47-51. PubMed ID: 18078397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Willebrand disease in the 21st century: current approaches and new challenges.
    Mannucci PM; Federici AB; James AH; Kessler CM
    Haemophilia; 2009 Sep; 15(5):1154-8. PubMed ID: 19624761
    [No Abstract]   [Full Text] [Related]  

  • 7. [Variant type von Willebrand disease with defective binding to factor VIII].
    Shima M
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):430-3. PubMed ID: 9833534
    [No Abstract]   [Full Text] [Related]  

  • 8. Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A.
    Mullah-Ali AM; Chan AK; Lillicrap D; Decker K; Seroski W; Moffat K; Walker I; Pai MK
    Haemophilia; 2009 Nov; 15(6):1258-61. PubMed ID: 19563498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of von Willebrand disease.
    Mannucci PM
    Int J Clin Lab Res; 1998; 28(4):211-4. PubMed ID: 9879493
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis in von Willebrand disease.
    Franchini M; Targher G; Lippi G
    Ann Hematol; 2007 Oct; 86(10):699-704. PubMed ID: 17634944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inborn and acquired von Willebrand disease].
    Schneppenheim R; Budde U
    Hamostaseologie; 2008 Dec; 28(5):312-9. PubMed ID: 19132162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis.
    Dong X; Leksa NC; Chhabra ES; Arndt JW; Lu Q; Knockenhauer KE; Peters RT; Springer TA
    Blood; 2019 Apr; 133(14):1523-1533. PubMed ID: 30642920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease.
    Trossaërt M; Flaujac C; Jeanpierre E; Drillaud N; Sigaud M; Fouassier M; Ternisien C; de Raucourt E
    Haemophilia; 2020 Mar; 26(2):e44-e48. PubMed ID: 31865618
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of von Willebrand disease.
    Mannucci PM
    Haemophilia; 1998 Jul; 4(4):661-4. PubMed ID: 9873811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone.
    Aguila S; O'Donnell JS
    J Thromb Haemost; 2019 Mar; 17(3):426-428. PubMed ID: 30652400
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical use of Haemate® P in von Willebrand disease: a 25-year retrospective observational study.
    Miesbach W; Krekeler S; Wolf Z; Seifried E
    Thromb Res; 2015 Mar; 135(3):479-84. PubMed ID: 25595881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Ewenstein BM; Reininger AJ
    Haemophilia; 2011 Sep; 17(5):e847-8. PubMed ID: 21752157
    [No Abstract]   [Full Text] [Related]  

  • 19. Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system.
    Ogiwara K; Nogami K; Hosokawa K; Ohnishi T; Matsumoto T; Shima M
    Haemophilia; 2015 Jan; 21(1):71-80. PubMed ID: 25545301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.